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Abstract
Background: The IgA1 protease of Streptococcus pneumoniae is a proteolytic enzyme that
specifically cleaves the hinge regions of human IgA1, which dominates most mucosal surfaces and
is the major IgA isotype in serum. This protease is expressed in all of the known pneumococcal
strains and plays a major role in pathogen's resistance to the host immune response. The present
work was focused at identifying the immunodominant regions of pneumococcal IgA1 protease
recognized by the human antibody response.
Results: An antigenic sequence corresponding to amino acids 420–457 (epiA) of the iga gene
product was identified by screening a pneumococcal phage display library with patients' sera. The
epiA peptide is conserved in all pneumococci and in two out of three S. mitis strains, while it is not
present in other oral streptococci so far sequenced. This epitope was specifically recognized by
antibodies present in sera from 90% of healthy adults, thus representing an important target of the
humoral response to S. pneumoniae and S. mitis infection. Moreover, sera from 68% of children less
than 4 years old reacted with the epiA peptide, indicating that the human immune response against
streptococcal antigens occurs during childhood.
Conclusion: The broad and specific recognition of the epiA polypeptide by human sera
demonstrate that the pneumococcal IgA1 protease contains an immunodominant B-cell epitope.
The use of phage display libraries to identify microbe or disease-specific antigens recognized by
human sera is a valuable approach to epitope discovery.
Background
Streptococcus pneumoniae is a human pathogen causing sig-
nificant morbidity and mortality worldwide. It is a tran-
sient member of the normal bacterial flora that colonizes
the upper respiratory tract of the host being a major cause
of various diseases such as otitis media, pneumonia, sep-
sis and meningitis. Despite the constant development of
therapeutics, antimicrobial drugs and vaccines, pneumo-
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dren, elderly people and immunocompromised
individuals [1,2]. In adults, pneumococcal infection is the
most common cause of community-acquired pneumonia
and otitis media and, since the introduction of vaccina-
tion against Haemophilus influenzae (serotype b) and Neis-
seria meningitidis also the most frequent cause of
meningitis.
Current immunization strategies focus on the use of S.
pneumoniae polysaccharides-based vaccines, employing
the 23-valent vaccine, which protects humans from two
years of age, and the 7-valent toxoid-conjugated vaccine,
used in children less than two years old [3,4]. However,
the available vaccines have several limitations due to the
low immunogenicity of capsular polysaccharides, the
high serotype variability and the genomic plasticity of this
bacterium. Therefore, in the last decade there has been a
great effort in developing improved vaccines to prevent
pneumococcal disease.
Several surface-associated proteins, which are well con-
served among the different strains of S. pneumoniae and
thus represent candidates of choice for the development
of novel vaccine formulations have been identified and
characterized. Among this class of proteins the immu-
noglobulin A1 (IgA1) protease is a promising candidate
since (i) it plays a major role in pathogen's resistance to
the host immune response [5,6], and (ii) it is present in all
pneumococcal strains and serotypes [7,8]. The impor-
tance of IgA protease is underlined by the fact that this
host-specific enzyme is conserved in other pathogens of
comparable disease and colonising similar niches [9-11].
The IgA1 protease is one of the two to four large zinc met-
alloproteinase present in the pneumococcal genome
[7,12]. The pneumococcal protease is a polypeptide of
about 1900 amino acids associated to the bacterium via
N-terminal anchoring [7,13-15]. It is a proteolytic enzyme
that specifically cleaves human IgA1 antibodies in the
hinge region of the immunoglobulin heavy chain [14,15].
Cross-inhibition experiments performed with sera from
immunized rabbits have revealed considerable serological
diversity of IgA1 proteases from different S. pneumoniae
strains [16]. Serological analysis indicated that the
sequence repeats domain of S. sanguis IgA1 protease was
immunogenic in rabbits and in humans, although the
antibodies recognizing this region did not inhibit enzyme
activity [17]. Specific antibodies reacting with IgA1 pro-
tease have been detected in sera from patients hospital-
ized for pneumococcal infection [18] as well as in young
children [19], highlighting the immunogenity of pneu-
mococcal IgA1 protease in humans.
The aim of this work was to identify the immunodomi-
nant epitopes of pneumococcal IgA1 protease involved in
the human antibody response against bacterial infection.
Results
In a recent study, we isolated several antigenic regions of
S. pneumoniae proteins by challenging a pneumococcal
genome display library with antibodies from one patient
infected by the bacterium [20]. In the present work a sim-
ilar approach was employed by using "ad-hoc" patients'
sera which displayed a low titer of antibodies against the
pneumococcal antigens identified in the previous study
(data not shown). Accordingly, sera from two patients
hospitalized for pneumococcal pneumonia were used for
a novel screening of the pneumococcal library. Phage
pools were analyzed after two round of affinity selection
and 30 out of 200 screened phage clones (15%) were iso-
lated by immunoscreening. Among them, 9 clones (30%)
contained insert encoding fragments of pneumococcal
IgA1 protease and 21 clones (70%) contained insert of
other bacterial proteins. At the end of the selection proce-
dure, 3 distinct phage clones whose DNA inserts matched
the sequence of the pneumococcal iga gene product were
identified: clone SP1, with a DNA insert encoding for a
protein fragment of 145 amino acids; clone SP2 encoding
for a polypeptide of 133 residues; clone SP4 encoding for
a polypeptide of 194 amino acids. As shown in Figure 1,
all the protein inserts of the selected phages contain a
common region of 72 amino acids corresponding to resi-
dues 420–493 of pneumococcal IgA1 protease (strain R6).
To characterize the biochemical and immunological
properties of the selected protein fragments independ-
ently from the phage display context, the DNA inserts of
phages SP2 and SP4 were subcloned into vector pGEX-SN
[21]. This resulted in the expression of GST fusion pro-
teins which were purified from E. coli cells under native
conditions by 1-step affinity chromatography. The recom-
binant proteins were efficiently expressed and purified in
large amounts from the cytoplasm of bacterial cells, with
the yields of purified GST-SP2 and GST-SP4 being 7 and 5
mg per liter of bacterial culture, respectively. Immunore-
activity of recombinant antigens with immunoglobulins
G (IgG) of human sera was examined. To this aim, an
enzyme-linked immunoassay was employed (Rec-ELISA).
The GST-SP2 and GST-SP4 fusion proteins were assayed
with 30 sera collected from healthy adults. As a control,
the IgG reactivity against wild-type GST protein was
assessed for each serum. The criterion used to assign a spe-
cific reactivity against single antigens was an ODGST-ANTI-
GEN greater than twice the ODGST. Both the SP2 and SP4
polypeptides specifically reacted with more than 80% of
serum samples (data not shown).Page 2 of 9
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the selected antigen fragments was investigated. To this
purpose, the common region of SP2 and SP4 protein frag-
ments, corresponding to amino acids 420–493 of pneu-
mococcal IgA1 protease was analyzed. Figure 2 shows the
alignment of this polypeptide of strain D39 to IgA pro-
teases of other pneumococci and related species. In strain
D39 such the sequence contains three 17 amino acid
repeats which are part of a region of the IgA protease
found to show high intraspecies conservation and a high
degree of interspecies variability [22]. Pneumococcal IgA
proteases fall in this region into two clusters: IgA1 pro-
teases in genomes of strains of serotypes 1, 2, 3, 4 and 6B
all have three repeats and a common downstream region
while other strains share a common downstream region
with S. mitis and have from two (type 23F), to seven (type
14), eight (type 19F) or even nine of these highly con-
served 17 amino acid repeats. The sequences of IgA pro-
teases of other oral streptococci such as S. sanguinis or S.
Comparison of streptococcal IgA1 protease sequencesFigure 2
Comparison of streptococcal IgA1 protease sequences. The protein region to which peptides epiA and epiB corre-
spond to amino acids 420–493 of the IgA1 protease of S. pneumoniae R6. The amino acid sequences are from S. pneumoniae 
type 2 strain R6 (U47687, Q54875), the type 4 strain TIGR4 (NC_003028), and the type 19F strain G54 (AL449925). The 
sequence of the type 6B strain 670 is from the TIGR Website [35]. BLAST comparisons to further sequences were done on 
the Sanger Website for the type 1 strain INV104B, the type 3 strain OXC141, the type 14 strain INV200 and the type 23F 
strain Spanish 23F-1 [36]. The S. mitis sequence is from GenBank AAY40355. Identical amino acid sequences are in white let-
ters on a black background.
 
         420               437               454               471                   493 
          |                 |                 |                 |                     | 
type_2    IQPELPEAVVSDKGEPE VQPTLPEAVVTDKGETE VQPESPDTVVSDKGEPE QVAPLPEYKGNIEQVKPETPVEK 
type_1    IQPELPEAVVSDKGEPE VQPTLPEAVVTDKGETE VQPESPDTVVSDKGEPE QVAPLPEYKGNIEQVKPETPVEK 
type_3    IQPELPEAVVSDKGVPE VQPALSEAVVTDKGETE VQPESSDTVVSDKGEPK QVAPLPEYKGNIEQVKPETPVEK 
type_4    IQPELPEAVVSDKGEPE VQPTLPEAVVTDKGETE VQPESPDTVVSDKGEPE QVAPLPEYKGNIEQVKPETPVEK 
type_6B   IQPELPEAVVSDKGVPE VQPALSKAVITDKGETE VQPESPDTVVSDKGEPE QVAPLPEYKGNIEQVKPETPVEK 
type_14   VQPELPEAVVSDKGEPA VQPELPEAVVTDKGETE VQPESPDTVVSDKGEPK QVAPLPEYTGPQASAIVEPEQVA 
type_19F  IQPELPEAVVTDKGEPA VQPELPEAVVTDKGETE VQPESPDTVVSDKGEPK QVAPLPEYTGPQASAIVEPEQVA 
type_23F  VQPELPEAVVSDKGVPE VQPALPEAVMTDKGDPE ----------------- QVEPLPEYTGVQAGAIVEPEKVE 
S.mitis   VQPALPEAVVTEKGEPA VQPELPEAVVTDKGETE VQPESPDTVVSDKGEPE QVAPLPEYKGPQAGAIVEPEQVA 
 
          |------------------epiA----------------||----------------epiB---------------| 
Schematic representation of the selected phage clonesFigure 1
Schematic representation of the selected phage clones. Alignment of the selected antigen fragments with the S. pneu-
moniae IgA1 protease of strain R6. The streptococcal IgA1 protease is typically organised in (i) a signal peptide (white box), (ii) 
a 200 amino acid N-terminal domain with three transmembrane segments and an LPXTG anchor domain (light grey box), (iii) a 
200 amino acid fibrillar domain (grey box), (iv) a region with repeat segments possibly involved in the binding of extracellular 
matrix components (empty box with arrows), and (v) a large central and C-terminal domain containing the active site of the 
protease (black box). The repeat segments in R6 are three repeats of seventeen amino acids with a conservation of 62 to 75% 
followed by two repeats of 78 amino acids with 64% identity. The common region of the antigen fragments in shown in diago-
nal bars.
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homology was detected.
Two GST fusion proteins, respectively carrying residues
420–457 (epiA) and 458–493 (epiB) of the IgA1 protease
from S. pneumoniae R6 strain were expressed. As shown in
Figure 3, the recombinant GST-epiA and GST-epiB anti-
gens were efficiently purified under native conditions
from transformed E. coli cells. Immunoreactivity of
recombinant antigens with IgG antibodies of human sera
was examined and the results were compared to those
obtained by use of the largest fragment of the IgA1 pro-
tease (clone SP4). The GST-epiA, GST-epiB and GST-SP4
antigens were assayed by Rec-ELISA with serum samples
from the two patients hospitalized for pneumococcal
pneumonia (used for the library selection) and from 46
healthy individuals. Immunoreactivity of wild-type GST
was also assessed for each serum. As shown in Table 1, the
recombinant GST-SP4, GST-epiA and GST-epiB proteins
specifically reacted with 44 (92%), 43 (89%) and 33
(69%) of the sera, respectively, highlighting a broad anti-
body recognition of all antigen fragments.
Because of the broad reactivity of the epiA fragment, its
recognition by antibodies present in sera from young chil-
dren was also investigated. Serum samples from forty chil-
dren with an age comprised between 1 and 4 years were
assayed with the recombinant GST-epiA antigen by Rec-
ELISA. As shown in Fig. 4, specific IgG antibodies against
the epiA polypeptide were detected in sera from the
majority of subjects (27 out of 40), thus demonstrating
Table 1: Immunoreactivity of the S. pneumoniae IgA1 protease 
antigen fragments PaP
Serum no. IgG Rec-ELISA (OD) PbP
GST-SP4 GST-epiA GST-epiB GST
PP1 2.47 2.62 2.13 0.26
PP2 2.19 1.63 0.45 0.10
S49 1.40 0.48 0.19 0.32
S50 1.74 1.52 0.23 0.24
S52 2.75 0.57 0.12 0.21
S53 0.42 0.23 0.28 0.08
S54 0.32 0.18 0.05 0.05
S58 1.80 0.94 0.75 0.06
S61 0.15 0.42 0.23 0.06
S62 0.44 1.47 0.29 0.13
S66 0.90 0.70 0.12 0.06
S67 0.31 0.39 0.25 0.25
S68 0.13 0.19 0.08 0.11
S69 1.22 0.24 0.12 0.11
S73 0.70 0.95 0.13 0.07
S74 0.44 0.42 0.34 0.06
S75 0.60 0.25 0.13 0.10
S76 1.64 1.72 0.43 0.08
S81 0.72 0.49 0.14 0.09
S82 0.06 0.07 0.05 0.05
S83 0.40 0.76 0.21 0.13
S84 1.01 0.73 0.16 0.07
S85 0.37 0.18 0.24 0.08
S87 0.11 0.22 0.15 0.13
S88 1.27 1.15 1.47 0.07
S89 0.46 0.61 1.34 0.15
S90 2.81 2.74 0.46 0.13
S92 0.90 0.90 0.44 0.05
S94 0.31 0.26 0.47 0.09
S96 0.52 0.54 0.60 0.06
S98 1.09 0.58 0.12 0.05
S100 2.01 0.64 0.89 0.06
S101 1.84 0.76 0.14 0.08
S102 0.56 0.22 0.10 0.04
S103 0.73 0.41 0.15 0.05
S104 0.39 0.40 0.49 0.03
S106 0.85 0.81 0.23 0.21
S107 0.67 0.30 0.27 0.05
S108 1.16 0.30 0.16 0.05
S109 0.55 0.17 0.11 0.05
S110 0.64 0.55 0.30 0.05
S111 0.75 0.46 1.31 0.05
S112 0.13 0.11 0.17 0.04
S113 1.52 0.53 0.34 0.07
S114 0.19 0.20 0.12 0.05
S115 1.66 1.76 1.90 0.04
S116 1.15 0.37 0.61 0.07
S117 2.07 1.90 2.20 0.18
Pa PSerum samples from patients with pneumococcal pneumonia (PP1 
and PP2) and from healthy adults (S49 to S117) were analyzed by IgG 
Rec-ELISA with individual recombinant proteins.
Pb PThe cutoff values were determined for each serum as two times 
the OD readings obtained with the GST. Boldface type, OD values 
greater than the cutoff values.
Characterization of the recombinant fusion proteinsFigure 3
Characterization of the recombinant fusion proteins. 
Purified proteins were subjected to SDS-PAGE analysis and 
loaded as follows: (1) and (7), molecular weight markers; (2) 
GST wild-type protein; (3) GST-SP2; (4) GST-SP4; (5) GST-
epiA; and (6) GST-epiB.
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antibodies against this short polypeptide.
Next, a detailed epitope mapping was performed employ-
ing affinity-purified antibodies. Specific immunoglobu-
lins against the GST-epiA fusion protein were purified
from 5 epiA-reactive sera and then assayed with the
recombinant GST-epiA, GST-epiB and GST-SP4 antigens
by Rec-ELISA. As a negative control, the IgG reactivity
against wild-type GST protein was also assessed. As shown
in Table 2, the affinity-purified anti-epiA antibodies spe-
cifically recognized both the epiA and epiB polypeptides
as well as the large SP4 fragment, indicating that a com-
mon epitope was present in the epiA and epiB protein
sequences.
Next, to exclude non-specific immunoreactivity due either
to altered conformation of the small polypeptides with
respect to native IgA1 protease or to cross-reactivity of
unrelated antibodies in human sera, a Western blot anal-
ysis was performed. To this aim, a whole cell lysate of S.
pneumoniae was challenged with the affinity-purified anti-
epiA antibodies. Bacterial lysates from pneumococcal iga-
deficient mutant strain FP174 and from Streptococcus gor-
donii were assayed as controls. As shown in Figure 5, a
unique protein band with an apparent molecular mass
higher than 220 kDa specifically reacted with the anti-
epiA antibodies in an unencapsulated strain of pneumo-
coccus (R6). In the FP174 mutant strain, in which the iga
gene was deleted, as well as in S. gordonii, such a protein
band was not visible, demonstrating that the anti-epiA
antibodies specifically recognized the pneumococcal
enzyme.
Finally, to investigate whether the epiA polypeptide is
exposed on the bacterium and is recognizable by anti-
epiA antibodies, a cell-ELISA analysis was performed on
whole S. pneumoniae cells. The FP174 strain was used as
the negative control. The affinity-purified anti-epiA anti-
bodies reacted with intact bacterial cells (strain R6) but
not with the iga-deleted FP174 strain (data not shown),
Recognition of pneumococcal iga gene product by affinity-purified anti-epiA antibodiesFigure 5
Recognition of pneumococcal iga gene product by 
affinity-purified anti-epiA antibodies. Western blot 
analysis on whole cell lysates from S. pneumoniae R6 (lanes 1 
and 4) and FP174 strains (lanes 2 and 5), and from S. gordonii 
(lanes 3 and 6). A homogeneous mixture of 5 human sera 
(lanes 1–3) or affinity-purified anti-epiA antibodies (lanes 
3–6) were used.
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Analysis of the B cell reactivity of the epiA peptide in healthy adults and c ildrenFigure 4
Analysis of the B cell reactivity of the epiA peptide in 
healthy adults and children. Immunoreactivity of the 
recombinant GST-epiA protein analyzed by IgG Rec-ELISA 
with serum samples from 48 blood donors and 40 children is 
shown. The values were calculated as the ratio of the OD 
readings obtained with the GST-epiA to twice the corre-
sponding OD readings obtained with the GST.
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Table 2: Cross-reactivity of epiA and epiB polypeptides with 
affinity-purified anti-epiA antibodies PaP
Antibody source IgG Rec-ELISA (OD) PbP
GST-epiA GST-epiB GST-SP4 GST
Sera mixture 2.802 1.332 2.866 0.256
Anti-epiA 
(150 ng mL-1)
2.107 2.124 2.274 0.092
Anti-epiA 
(30 ng mL-1)
0.601 0.609 0.660 0.047
Pa PRecombinant antigens were PPanalyzed by IgG Rec-ELISA with a 
homogeneos mixture of human sera (diluted 1:50) or with affinity-
purified anti-epiA antibodies
Pb PThe cutoff values for the IgG Rec-ELISA with the recombinant 
GST-epiA, GST-epiB, and GST-SP4 proteins were calculated as two 
times the OD readings obtained with the GST. Boldface type, OD 
values greater than the cutoff values.Page 5 of 9
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repeats of the pneumococcal enzyme is indeed exposed in
the native state. Noteworthy, our results are in close agree-
ment with a previous work where it was demonstrated
that the tandem repeats of S. sanguis IgA1 protease contain
immunodominant epitopes exposed in the denatured and
native state [16].
Discussion
Bacterial IgA1 proteases are highly specific endopepti-
dases that are secreted by a small number of bacteria asso-
ciated with humans [23,24]. IgA1 protease-producing
bacteria include the mucosal pathogens N. meningitidis,
N. gonorrhoeae, H. influenzae, S. pneumoniae, U. urealyticum
and some members of pharyngeal microfloras such as
Prevotella, Gemella haemolysans, S. sanguis, S. oralis and S.
mitis [14,22]. The importance of this bacterial enzyme in
the interaction with the host is evidenced by the fact that
most of these enzymes are specific for human IgA only,
and that their impact on the host is so great as to become
one of the few recognised factors of positive evolutionary
selection on the human genome [25]. For the bacterial
pathogens colonizing mucosal surfaces, IgA1 protease
production represents a virulent factor and contributes to
the pathogenesis of invasive infection by cleaving the Fc
receptor from secreted immunoglobulins A1, thus pre-
venting opsonophagocytosis [5]. IgA1 proteases have
been shown to be targets of enzyme-neutralizing antibod-
ies in serum and secretions [26], which may be induced in
a state of bacterial carriage as well as during invasive infec-
tion [27].
We previously demonstrated the potential of phage-dis-
play technology in identifying B-cell epitopes recognized
by the human immune response against Toxoplasma gondii
and S. pneumoniae infection [20,28-30], even though such
a technique usually favors the identification of linear
epitopes whereas conformational epitopes are often over-
looked. Nevertheless, the present work allowed the iden-
tification of antigenic regions of the pneumococcal IgA1
protease that are broadly recognized by human antibod-
ies. Challenging a lambda-display library of S. pneumoniae
with sera from patients hospitalized for pneumococcal
pneumonia enabled the selection of three distinct clones
harboring a common region of the IgA1 protease. All
clone sequences matched the pneumococcal enzyme
encompassing amino acids 360–590. The immunoreac-
tivity of the selected fragments, expressed as GST fusion
products, was assessed; overall, IgG antibodies in serum
samples from more than 90% of healthy adults reacted
with at least one antigen fragment, which emphasizes the
broad recognition of pneumococcal IgA1 protease by the
human B cell response.
Because of the broad reactivity of the selected IgA1 pro-
tease fragments, a detailed characterization of their com-
mon region, composed by 72 amino acids, was
performed. This lead to classify the sequence correspond-
ing to residues 420–457 (epiA peptide) of the iga gene
product as the most reactive polypeptide, which was rec-
ognized by antibodies present in sera from 90% of
healthy adults and 68% of children with an age comprised
between 1 and 4 years, thus suggesting that the human
antibody response against IgA1 protease occurs during
childhood. Noteworthy, our data are in agreement with a
previous study showing that IgG antibodies from the
majority of children less than two years old specifically
reacted with pneumococcal antigens, including the IgA1
protease [19].
The evidence that affinity-purified anti-epiA antibodies
also reacted with the epiB fragment (residues 458–493)
indicated that a common epitope within polypeptides
was recognized by human sera. Notably, a repeated 9-mer
sequence VVTDKGEPE is present twice in epiA and once
in epiB fragments (Fig. 1 and 2). This duplication might
account for the larger reactivity of the epiA peptide with
respect to the epiB peptide.
The IgA1 protease of S. pneumoniae is a major antigen
expressed in all known pneumococcal strains [7]. Despite
the pneumococcal enzyme has a peculiar structure among
bacterial proteases, homology searches have indicated
that the iga gene of S. pneumoniae is also found in other
streptococci and related organisms [8,14,15,22]. As
already noted by others, the repeats region shows high
conservation within the different pneumococcal strains
and between S. pneumoniae and the most closely related S.
mitis (90% identity), while homology to IgA proteases
from other streptococci is significantly lower in this seg-
ment when compared to the rest of the molecule [8,22].
The epiA peptide identified in this work is conserved in all
pneumococci and in two out of three S. mitis strains [22],
while it is not conserved in other oral streptococci
sequenced so far. The fact that the domain covered by
epiA is not shared with oral streptococci other than S.
mitis suggests that this domain is probably not inter-
changeable, which reduces the risk of escape mutants by
horizontal gene transfer. In other words, this would indi-
cate that any reservoir of divergent IgA1 proteases in non
pneumococcal species should not be imported readily by
recombination into pneumococcus.
We have shown here that an immunodominant polypep-
tide (epiA peptide), located within the sequence repeats
domain of pneumococcal IgA1 protease, is well conserved
among several serotypes and strains of S. pneumoniae but
not to the corresponding regions of the iga gene products
from other streptococci such as S. oralis, S. sanguis and S.Page 6 of 9
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homology of this protein region between S. pneumoniae
and S. mitis (see Fig. 2), suggesting that the observed high
rate of seropositivity against pneumococcal IgA1 protease
might be due to early colonization with bacteria species
other than pneumococcus.
Conclusion
The broad and specific recognition of the epiA polypep-
tide by human sera demonstrates that the pneumococcal
IgA1 protease contains an immunodominant B-cell
epitope. In perspective, it will be of great interest to inves-
tigate the ability of the anti-epiA antibodies in conferring
protective immunity against S. pneumoniae infection in
animal models. The use of phage display libraries to iden-
tify microbe or disease-specific antigens recognized by the
human sera is a promising and valuable approach to
epitope discovery.
Methods
Bacterial strains
Bacteria were grown in tryptic soy broth (TSB) in a 5%
COB2B-enriched atmosphere at 37°C. Where necessary,
streptomycin and kanamycin were used at a final concen-
tration of 500 μg mLP-1P. Streptococcus pneumoniae R6 [31],
FP174 (ΔSP1154/iga) [12] and S. gordonii [32] strains
were used for this study.
Affinity selection of the S. pneumoniae display library and 
serum samples
Serum samples from two patients with a respective age of
2 and 64 years old, collected during patient's hospitaliza-
tion for acute pneumococcal pneumonia, were used for
the affinity selection of a whole genome lambda-display
library of S. pneumoniae D39 strain [20]. The construction
of the pneumococcal library and the selection of the
library with human sera were performed as previously
described [33]. Briefly, magnetic beads linked to Protein
G (Dynal, Norway) were incubated for 40 min at room
temperature with 10 μL of serum. Beads were then incu-
bated with 5 × 1010 plaque forming units (PFU) of the
phage library (complexity of the library, 2 × 107 independ-
ent clones) for 3 hours at room temperature. Escherichia
coli cells were infected with phage pools by mixing the
beads and the bacterial cells, and recombinant phages
were amplified by using standard procedures [34]. After
two rounds of affinity selection, single phage clones were
isolated from phage pools by immunoscreening [28].
Forty-eight serum samples collected from 48 blood
donors were anonymously collected and then used for the
analysis of selected antigen fragments' immunoreactivity.
Forty sera from 40 children born to mothers with congen-
ital infections in pregnancy (i.e. Toxoplasma gondii and
human cytomegalovirus infection) and referred for post-
natal follow up of congenital diseases were also included
in the study. Sera were collected from children with
asymptomatic diseases with an age comprised between 1
and 4 years, and the serum samples were assayed in a
blinded fashion.
Cloning and recombinant protein expression and 
purification
DNA inserts of phage clones SP2 and SP4 were amplified
by PCR, digested with Spe I and Not I endonucleases and
subcloned into the bacterial vector pGEX-SN [21]. DNA
fragments encoding for amino acids 420–457 and amino
acids 458–493 of the S. pneumoniae IgA1 protease (Gen-
Bank Q54875) were PCR amplified from phage clone SP4
by using oligonucleotides K708 (5'-ACGACTAGTGCAAT-
TCAGCCTGAGT TGCCC-3') and K709 (5'-GGTGCG-
GCCGCTCACTCTGGTTGAACCTCAGTCTC-3'), and
oligonucleotides K710 (5'-CGAACTAGT TCGCCAGA-
TACTGTGGTAAG-3') and K711 (5'-GGTGCGGCCGCT-
CACTTCTCAACCGGAGTTTCAC-3'), respectively. PCR
products were digested with Spe I and Not I enzymes and
then cloned into pGEX-SN plasmid. Competent
Escherichia coli cells (AD202 strain) [34] were transformed
with recombinant plasmids and single clones were iso-
lated.
Recombinant proteins produced in E. coli as fusion pro-
teins with glutathione S-transferase (GST) were purified
from the cytoplasm of bacterial cells by affinity chroma-
tography, as previously described [29]. Briefly, recom-
binant E. coli was induced with isopropyl-
thiogalactopyranoside (IPTG), centrifuged and suspended
in 10 mM Tris-HCl (pH 8), 150 mM NaCl, 100 μg mL-1 of
lysozyme and protease inhibitors (Boheringer, Germany).
The mixture was sonicated, and Triton-X100 was added to
a final concentration of 1%. After centrifugation at 10,000
× g for 30 min at 4°C, the supernatant was incubated with
Glutathione-Sepharose (Amersham-Pharmacia Biotech,
Sweden) and GST-proteins were eluted by following the
manufacturer's instructions. Finally, protein purity and
content were assessed by sodium dodecyl sulfate-polyacri-
lamide gel electrophoresis (SDS-PAGE) and by Bradford
assays, respectively.
Recombinant protein enzyme-linked immunoassays (Rec-
ELISA)
Maxisorb multiwell plates (Nunc) were adsorbed with
recombinant proteins (GST-SP2, GST-SP4, GST-epiA,
GST-epiB and GST) at a concentration of 5 μg mL-1 in 50
mM NaHCOB3B, pH 9.6. After incubation overnight at
4°C, the plates were blocked with 5% non-fat dry milk
and 0.05% Tween-20 in PBS (blocking buffer) and incu-
bated for 1 h at 37°C with serum samples diluted 1:50 in
blocking buffer. The plates were washed with 0.05%
Tween-20 in PBS, and anti-human IgG horseradish perox-Page 7 of 9
(page number not for citation purposes)
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then added to each well. Finally, incubating the plates
with the chromogenic substrate tetramethylbenzidine
(TMB; Sigma Aldrich) revealed the enzymatic activity. The
results were recorded as the difference between the
absorbance (optical density, OD) at 450 and at 620 nm,
as detected with an automated ELISA reader (Labsystem
Multiskan, Finland). Assays were performed in duplicate,
and average values were calculated. GST carrier protein
was used as the negative control in every assay.
Purification of anti-epiA antibodies from human sera
The GST-epiA fusion protein was immobilized to a NHS-
activated-agarose column (Amersham-Pharmacia Bio-
tech, Sweden) in accordance with the manufacturer's
instructions. A mixture of sera from five blood donors
(sera S90, S117, S115, S62 and S76) were allowed to flow
through the column overnight to permit the binding of
specific antibodies to the recombinant protein. After
extensively washing the column with PBS and then with a
solution containing 0.5 M NaCl in PBS, the antigen-spe-
cific antibodies were eluted with a solution of 50 mM gly-
cine (pH 3) containing 100 mM NaCl. The antibody
concentration was determined by Bradford assay.
Western blot analysis
S. pneumoniae strains R6 and FP174 and S. gordonii strain
Challis [32] were grown in 15 mL of Tryptic Soy Broth
(TSB, BD Biosciences) in standard conditions. Cells were
collected by centrifugation at 3000 g for 15 min at 4°C
and washed with PBS. Bacteria were suspended in a final
volume of 0.5 mL of loading buffer (10 mM Tris-HCl, 1
mM EDTA, 1% SDS, 10 mM dithiothreitol, 10% glycerol,
0.01% bromophenol blue), heated for 15 min at 95°C
and then subjected to SDS-PAGE. Proteins were trans-
ferred onto nitrocellulose membranes (BioTrace NT, Pure
Nitrocellulose Blotting Membrane, Pall Life Science),
which were subsequently blocked with 5% non-fat dry
milk and 0.05% Tween-20 in PBS (blocking buffer). The
filters were incubated overnight at 4°C with the affinity-
purified anti-epiA antibodies used at a concentration of
150 ng mL-1. After being extensively washed with 0.05%
Tween-20 in PBS, filters were incubated with anti-human
IgG alkaline phosphatase-conjugated antibodies (Sigma-
Aldrich, USA). Finally, protein bands were visualized by
using nitroblue tetrazolium (NBT; Sigma Aldrich) and 5-
bromo-4-chloro-3-indosyl phosphate (BCIP; Sigma
Aldrich) as choromogenic substrates.
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